Innohep (Tinzaparin Sodium)

Innohep, a low molecular weight heparin, is used in several clinical situations to prevent or treat thromboembolic disorders.

• Prevention of deep vein thrombosis in surgical patients: reduces the incidence of postoperative clot formation.
• Treatment of deep vein thrombosis: facilitates clot resolution and prevents extension.
• Prevention of pulmonary embolism: lowers the risk of embolic events in at‑risk individuals.
• Prevention of clot formation in hemodialysis: maintains circuit patency during dialysis sessions.

• Tinzaparin sodium binds to antithrombin III, markedly accelerating its inhibition of activated factor Xa and, to a lesser extent, factor IIa (thrombin). This reduces thrombin generation and fibrin formation, thereby interrupting the coagulation cascade and preventing the development and propagation of thrombotic clots. The selective inhibition of factor Xa provides a predictable anticoagulant effect with a lower risk of platelet interaction compared with unfractionated heparin.

Tinzaparin sodium may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Injection site erythema: redness at the subcutaneous injection site.
• Pain or bruising: mild discomfort or discoloration around the injection area.
• Minor bleeding: nosebleeds, gum bleeding, or easy bruising.
• Elevated liver enzymes: transient increase in hepatic transaminases.

Serious or Rare Side Effects

• Major bleeding: life‑threatening hemorrhage such as gastrointestinal or intracranial bleeding.
• Heparin‑induced thrombocytopenia (HIT): immune‑mediated platelet drop with paradoxical clotting.
• Spinal or epidural hematoma: bleeding in the spinal canal following neuraxial procedures.
• Anaphylactic reaction: severe allergic response requiring immediate medical attention.
• Skin necrosis: localized tissue death at injection sites.

When using Innohep, several precautionary measures should be observed to minimize risk.

• Renal impairment: adjust dosing and monitor anti‑Xa activity.
• History of heparin‑induced thrombocytopenia: avoid use due to risk of recurrence.
• Concurrent anticoagulants or antiplatelet agents: assess cumulative bleeding risk.
• Recent surgery or trauma: evaluate for potential bleeding complications.
• Pregnancy and lactation: use only if the expected benefit outweighs potential risk.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Tinzaparin sodium can interact with other medicines, altering bleeding risk or anticoagulant effect.

Major Interactions (Avoid)

• Concomitant use with other anticoagulants (e.g., warfarin, direct oral anticoagulants): markedly increases risk of severe bleeding.
• Antiplatelet agents (e.g., aspirin, clopidogrel): additive effect on bleeding.
• Thrombolytic therapy (e.g., alteplase): synergistic hemorrhagic potential.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may enhance minor bleeding.
• Selective serotonin reuptake inhibitors (SSRIs): can increase bleeding tendency.
• Systemic corticosteroids: may exacerbate bleeding risk.